Gainers
- DIH Holding US DHAI shares rose 35.1% to $0.34 during Friday's after-market session. The company's market cap stands at $11.2 million.
- TNF Pharmaceuticals TNFA stock increased by 25.71% to $0.11. The market value of their outstanding shares is at $1.3 million.
- HCW Biologics HCWB stock rose 25.33% to $5.64. The company's market cap stands at $9.7 million.
- GlucoTrack GCTK shares increased by 14.75% to $6.69. The market value of their outstanding shares is at $3.3 million.
- OSR Holdings OSRH stock increased by 12.14% to $1.2. The company's market cap stands at $19.2 million.
- Abivax ABVX shares rose 9.54% to $10.9. The company's market cap stands at $656.2 million.
Losers
- Cyclacel Pharmaceuticals CYCC stock declined by 9.7% to $11.81 during Friday's after-market session. The market value of their outstanding shares is at $13.0 million.
- Clene CLNN shares declined by 8.26% to $3.5. The market value of their outstanding shares is at $35.0 million.
- Aptorum Group APM shares fell 6.22% to $1.51. The company's market cap stands at $14.0 million.
- VSee Health VSEE stock decreased by 5.11% to $1.3. The market value of their outstanding shares is at $22.1 million.
- Lexaria Bioscience LEXX shares fell 5.0% to $0.9. The company's market cap stands at $15.2 million. As per the press release, Q3 earnings came out 4 days ago.
- cbdMD YCBD shares fell 4.73% to $0.92. The company's market cap stands at $8.2 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
ABVXAbivax SA
$10.293.42%
Edge Rankings
Momentum
80.23
Price Trend
Short
Medium
Long
APMAptorum Group Ltd
$1.641.86%
CLNNClene Inc
$3.881.57%
CYCCCyclacel Pharmaceuticals Inc
$12.00-8.19%
DHAIDIH Holding US Inc
$0.275010.9%
GCTKGlucoTrack Inc
$8.0037.2%
HCWBHCW Biologics Inc
$4.39-2.44%
LEXXLexaria Bioscience Corp
$0.95000.48%
OSRHOSR Holdings Inc
$1.081.87%
TNFATNF Pharmaceuticals Inc
$0.120037.1%
VSEEVSee Health Inc
$1.360.74%
YCBDcbdMD Inc
Not Available-%
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.